Daniel Philip Nussbaum

Journal Article Ann Surg · December 1, 2025 OBJECTIVE: To sought comprehensively profile tissue and cyst fluid in patients with benign, precancerous, and cancerous conditions of the pancreas to characterize the intrinsic pancreatic microbiome. BACKGROUND: Small studies in pancreatic ductal adenocarc ... Full text Link to item Cite

Preparing for the Inevitable: Early Comprehensive Genomic Profiling for Patients With Localized Pancreatic Ductal Adenocarcinoma.

Journal Article JCO Oncol Pract · November 14, 2025 PURPOSE: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal disease, even for patients diagnosed at a radiographically localized stage. Despite disease recurrence in most patients who undergo curative-intent therapy, national guidelines do not curr ... Full text Link to item Cite

Comparing traditional versus total neoadjuvant chemotherapy for patients with localized pancreatic cancer.

Journal Article HPB (Oxford) · November 7, 2025 Full text Link to item Cite

View All Publications

Recent Grants

A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFolfirinox versus mFolfirinox alone in Patients with Resected Pancreatic Ductal Adenocarcinoma Protocol G044479

Clinical TrialPrincipal Investigator · Awarded by Genentech, Inc. · 2023 - 2033

Advanced Immunobiology Traning Program for Surgeons

Inst. Training Prgm or CMEMentor · Awarded by National Institute of Allergy and Infectious Diseases · 2019 - 2029

Single Cell and Spatial Analysis of Lethal Breast Cancers

ResearchCo Investigator · Awarded by Department of Defense · 2024 - 2028

View All Grants

Education, Training & Certifications

University of Southern California · 2011 M.D.

University of Wisconsin, Madison · 2006 B.S.